Guide contents
Open in calculatorCompound briefing
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). It retains the potent anti-inflammatory activity of the parent hormone without its pigmentation or appetite effects, and is studied across inflammatory bowel disease, dermatological inflammation, mast-cell modulation and wound healing.
The research question
KPV retains anti-inflammatory activity associated with part of α-MSH without sharing every effect of the parent hormone. NF-κB signalling and epithelial inflammation are central themes, particularly in intestinal and skin models.
Mechanism & research themes
Enters cells and translocates to the nucleus to inhibit NF-κB activation, suppressing downstream pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). Also stabilises mast cells and modulates innate immune responses.
Broad anti-inflammatory activity via NF-κB suppression
Improved outcomes in IBD and colitis animal models
Reduced inflammatory dermatological lesions in research
Mast-cell stabilisation relevant to allergic and MCAS research
Antimicrobial activity against several common pathogens
Favourable tolerability with minimal reported side effects
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Most direct evidence comes from cell and animal inflammation models. Oral, topical and injectable routes pose different bioavailability questions and should be assessed separately.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 200–500mcg subcutaneously once daily, or higher oral/encapsulated doses (approximately 500mcg–1mg) for gut-targeted protocols. Cycles typically run 4–8 weeks.
Reported persistence
Plasma half-life is short (approximately 30–60 minutes); local tissue effects persist longer.
Calculator starting point
0.5 mg per reference dose
7 doses per week · 4-week cycle
2 mL default reconstitution volume
200–500 mcg/day SC, short cycles.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate KPVLaboratory handling
Reconstitution reference
Reconstitute a 10mg vial with 2–4mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently.
Storage reference
Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Human RCT data remains limited; most evidence is preclinical or early-phase.
Oral bioavailability is modest — encapsulation or compounding is typically required for gut-targeted use.
Long-term safety dataset is not yet well characterised.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading